CancerGuide Diagnostics, Inc., a life science company focused on the development and commercialization of genomic-based clinical and pharmaceutical cancer tests and services, enabling physicians, patients, and researchers to make individualized treatment or drug discovery decisions, has completed the first tranche of a $10.5m round of private financing.
The round was co-led by Hatteras Venture Partners and Intersouth Partners, with participation from Laboratory Corporation of America Holdings (LabCorp).
In addition, the company signed a multi-year, strategic collaboration and license agreement with LabCorp.
Under the agreement, LabCorp and CancerGuide will collaborate in the development and commercialization of CancerGuide’s molecular oncology assays.
FinSMEs
04/02/2010